Introduction
Oncogenes and tumor suppressor genes are generally considered to regulate developmental and differentiation processes, and the deregulation of these genes enables the development of cancer (Bishop, 1983) . Three members of the Runt-related (RUNX) family genes, RUNX1, RUNX2 and RUNX3, and related gene, CBFB/ Pebpb2, are all known developmental regulators and have been shown to be important in human cancers or experimentally induced mouse tumors.
RUNX genes encode the a subunits (polyomavirus enhancer-binding protein 2 (PEBP2)a/core-binding factor (CBF)a) of the Runt domain transcription factors (which act as developmental regulators) and combine with the b subunits (PEBP2b/CBFb) to form the heterodimeric transcription factor initially discovered as the PEBP2, or the CBF, which interacts with the enhancer core of Moloney murine leukemia virus. The cDNA sequences encoding the a and b subunits revealed that the a subunit gene is a homolog of the Drosophila segmentation gene, runt. Unrelated investigations determined that RUNX1/AML1 is a gene on chromosome 21 involved in the breakpoint of the chromosome translocation t(8;21) associated with acute myelogenous leukemia. Furthermore, the gene encoding PEBP2b/ CBFb, CBFb/Pebpb2, is also involved in the recurrent chromosome rearrangement [inv(16) ] associated with acute myelogenous leukemia.
Roles of the RUNX family genes have now been described in many different biological systems and in different animal species in this rapidly expanding research field. In this Review, discussion will focus mainly on recent research developments involving oncogenic activities of RUNX and related genes. I will summarize in this Overview developments and potential future problems in RUNX research.
Historical note
The polyomavirus enhancer was used as a probe to explore mouse cell differentiation 20 years ago, when virtually no other molecular approaches were available to examine differentiation of mouse embryos (Amati, 1985) . Virologists found that embryonal carcinoma cell lines, such as F9 and PCC4, are resistant to infection by several viruses including polyomavirus until cells are induced to differentiate. Furthermore, the polyomavirus enhancer determines the differentiation of stage-specific viral infections and, therefore, attempts have been made to identify the transcription factors responsible for this activity (Katinka et al., 1980; Tanaka et al., 1982) . The PEBP2 (Satake et al., 1992) is not synthesized in embryonal carcinoma cells, but is expressed when the cells undergo differentiation. PEBP2 is indeed a developmental regulator and, therefore, was one of the factors initially probed with the polyomavirus enhancer in the early study of differentiation in mouse embryo development. Kamachi et al. (1990) first purified PEBP2 from H-ras-transformed NIH3T3 cells and disclosed that this factor is a heterodimer of two chemically distinct subunits, a and b, and that its optimal recognition sequence is PuACCPuCA. Ogawa and her co-workers subsequently cloned cDNA for both subunits using degenerate oligonucleotides based on the partial amino-acid sequences. From this approach, full-length murine PEBP2aA cDNA, now called Runx2, and the PEBP2b cDNA were identified (Ogawa et al., 1993a b) .
Moloney murine leukemia virus induces thymoma in mice. The viral enhancer, or enhancer core element, located in the long terminal repeat is responsible for this disease specificity. Investigation of the tissue tropism of viral infections or tumor formation revealed a CBF (Speck et al., 1990) . Nancy Speck's laboratory purified CBF from bovine calf thymus, partial amino-acid sequences were obtained, degenerate oligonucleotides were synthesized and the CBFb cDNA was cloned (Wang and Speck, 1992; Wang et al., 1993) . The cDNA sequences of PEBP2b and CBFb are identical.
Misao Ohki's group attempted to identify the genes involved in the most frequently observed chromosome translocation in acute myelogenous leukemia, t(8;21). Their skillful analyses of the large segments of genomic sequences enabled the identification of the human AML1 gene on chromosome 21 using the cell line obtained from an acute myelogenous leukemia patient (Miyoshi et al., 1991) . The cDNA sequence of human AML1 is highly homologous to that of one of the Drosophila segmentation genes of the primary pair-rule class, runt, reported earlier by Peter Gergen's laboratory (Kania et al., 1990) . The mouse PEBP2aA is also homologous to these two genes, although AML1 and PEBP2aA represent two separate genes in the mammalian genome.
The developmental role of Drosophila runt (Kania et al., 1990) and the involvement of AML1 in human leukemia was obvious at the beginning of the 1990s (Miyoshi et al., 1991) . PEBP2, which was already known to function as a heterodimeric transcription factor, was predicted to be a developmental regulator. Furthermore, PEBP2aA was clearly identified as the a subunit, or the DNA-binding subunit of PEBP2, which requires the b subunit, PEBP2b, for strong binding to DNA (Ogawa et al., 1993a, b) . Thus, it became apparent that this family of genes encodes developmental regulators and transcription factors and requires the b subunit to form a heterodimer. Indeed, the b homolog was found in Drosophila and AML1 formed a heterodimer with PEBP2b. Furthermore, the mammalian genes of this family were suspected to be involved in human cancers. In addition, the location of the evolutionarily conserved region and the domain structures became obvious only after the cDNA sequences of Runt, AML1 and PEBP2aA and their deduced amino-acid sequences were compared. Nearly 70% of the amino acids in the conserved 128 amino-acid region of the three gene products were identical and the region was termed the Runt domain (Kagoshima et al., 1993) . (The authors carefully avoided naming it the Runt homology domain (RHD) to avoid confusion with the widely used Rel homology domain. Unfortunately, some researchers use the term RHD in reference to the Runt domain.) The five amino-acid sequence, VWRPY, was also noted at the C-terminal end of all three gene products. [The first report of the AML1 cDNA sequence by Miyoshi et al. (1991) was a splice variant, later termed AML1a, but the full-length cDNA was later isolated and termed AML1b, which encodes the VWRPY sequence (Miyoshi et al., 1995) .] We noted a curious similarity that the product of Drosophila hairy, another segmentation gene of primary pair-rule class, has the evolutionarily conserved four amino-acid sequence WRPW (Paroush et al., 1994) at the C-terminus to which the transcriptional repressor Groncho binds. The mammalian homolog of Groucho, TLE, was found later to interact with VWRPY (Levanon et al., 1998; Imai et al., 1998) .
The mammalian genes and splice variants of related cDNAs homologous to runt, AML1 and PEBP2aA, were subsequently identified by cDNA sequence homology by several laboratories. The third gene, RUNX3/ AML2/PEBP2aC/CBFA3, was reported by Levanon et al. (1994) and Bae et al. (1995) . Distal and proximal promoters were identified during the cloning of related cDNAs. We now know that there are three a subunit genes in mammals. So far, four genes have been reported in zebra fish (Kataoka et al., 2000; Crosier et al., 2002; Burns et al., 2002; Vega-Flores et al., unpublished; Runx2a (AAQ88390) and Runx2b (AAR29000)), one in Xenopus (Tracey et al., 1998) , four in Drosophila, runt, lozenge RunxA and RunxB (Kania et al., 1990; Daga et al., 1996; Rennert et al., 2003) , one in sea urchin (Coffman et al., 1996) , and one (run) in Caenorhabditis elegans (Nam et al., 2002) . Drosophila lozenge was first described by Utpal Banerjee as a key regulator of eye development in cell fate determination. Later, lozenge was found also to be involved in the differentiation of Drosophila hematopoietic cells (Lebestky et al., 2000) . As a vertebrate model system for hematopoiesis, the zebra fish has played a significant role in complementing studies of mammalian hematopoiesis.
Since the three mammalian genes homologous to runt have a variety of names, common names for these genes have been adopted by researchers primarily responsible for the isolation of the corresponding cDNAs, including Misao Ohki, Peter Gergen, Nancy Speck, Paul Liu, Scott Hiebert, Yorum Groner, James Neil and myself under the coordination of Andre van Wijnen and Gary Stein in 1999-2000. The most favored name was RUNX (Runt-related) gene. The details and background of this discussion are described by van Wijinen et al. in this issue. Thus, each of the names within each of the following three clusters is identical to the RUNX nomenclature shown at the beginning of the cluster. The three RUNX genes are: RUNX1/AML1/PEBP2aB/ CBFA2, RUNX2/AML3/PEBP2aA/CBFA1 and RUNX3/AML2/PEBP2aC/CBFA3. Paul Liu in Francis Collins's laboratory identified the chimeric gene involved in the recurrent chromosome rearrangement, inv(16), associated with the M4Eo subtype of acute myeloid leukemia. The gene encodes PEBP2b/CBFb fused to the smooth muscle myosin heavy chain (SMMHC) gene, MYH11 (Liu et al., 1993) . This discovery revealed the PEBP2b/CBFb gene as a potentially important leukemogenic gene and suggested that RUNX1/AML1 and PEBP2b/CBFb function together as partners of a heterodimeric transcription factor. In fact, the phenotypes of the Runx1/Aml1-and PEBP2b/CBFb-null mice were nearly identical (Okuda et al., 1996; Wang et al., 1996a b; Niki et al., 1997; Okada et al., 1998) strongly supporting the notion that they function together. These results biologically validated the biochemical evidence that the RUNX protein and PEBP2b/CBFb form a heterodimeric transcription factor, as demonstrated primarily in the laboratories of Nancy Speck and Katsuya Shigesada and in my own laboratory. PEBP2b/CBFb interacts with RUNX2 and RUNX3 as well. All the in vivo evidence thus far indicates the requirement of PEBP2b/ CBFb for the function of the RUNX family proteins.
Only one PEBP2b/CBFb gene is present in the mammalian genome. The official gene designate for the human gene is CBFB. The mouse Pebpb2 gene is also registered (Bae et al., 1994) . Two genes, brother and big brother, exist in Drosophila (Golling et al., 1996) .
Three-dimensional structure
The three-dimensional structure of the Runt domain was determined by NMR in the laboratories of Milton Werner in collaboration with Katsuya Shigesada and myself (Nagata et al., 1999) and John Bushweller in collaboration with Nancy Speck (Berardi et al., 1999) , and by crystallography by Alan Warren (2000) . The NMR structure of the 134 amino-acid region of PEBP2b/CBFb, which encompasses the heterodimerization domain, was also determined by Werner's and Bushweller's laboratories (Goger et al., 1999; Huang et al., 1999) . The crystal structure of the Runt domain together with PEBP2b bound to DNA was determined by Tahirov and Ogata's laboratory (Tahirov et al., 2001) . This DNA-bound structure is shown in Figure 1 . In the three-dimensional topology, the Runt domain proved to have an S-type immunoglobulin fold, which is closely related to that of STAT-3.
Comparison of the amino-acid sequences of the RUNX proteins in various species reveals the domain structure of the proteins as shown in Figure 2 . The position of the highly conserved Runt domain and VWRPY motif at the C-termini are well recognized. Conservation of the so-called PY motif, PPxY, is also remarkable. The functions of other conserved regions are yet to be determined. The function of the unique polyglutamine region followed by polyalanine sequences in RUNX2 is unclear at the moment.
A diagrammatic comparison of the major features of the RUNX1, RUNX2 and RUNX3 proteins is shown (Figure 3 ). RUNX1 functional domains, sites of phosphorylation and acetylation, and interacting proteins are shown in Figure 4 .
Genomic structure of the RUNX genes
Runt-related genes can be traced evolutionarily back to C. elegans that has one Runt-related gene, run (Nam et al., 2002) . Levanon and Groner studied a possible evolutionary pathway of run to the current three genes in mammals, and found that RUNX1 is the largest in the family and spans 260 kb having 11 exons, while RUNX3 is the smallest and spans about 67 kb having six exons. Based on genomic structure complexity, they proposed that RUNX3 is the most primitive of the three genes (Bangsow et al., 2001) . However, more detailed analyses appear to be required to determine precisely the chronology of evolutional diversification of the genes (Rennert et al., 2003) . Nevertheless, it is interesting to note that Runx3 is involved in the development of primitive monosynaptic neurons (Levanon et al., 2002; Inoue et al., 2002) . In C. elegans, run is expressed in gut cells as well as in other cell types (Nam et al., 2002) . Sea urchins also contain one Runx gene that is expressed in foregut (Robertson et al., 2002) . Therefore, RUNX3 function in the stomachs of mammals may be evolutionarily conserved.
RUNX1 and leukemia
RUNX1 has important roles in hematopoiesis and its functional dysregulation leads to leukemia. The major physiological function of RUNX1 was first revealed when mouse Runx1 was disrupted by a targeting strategy used by Jim Downing (Okuda et al., 1996) , Nancy Speck (Wang et al., 1996a) and Masanobu Satake (Okada et al., 1998) . RUNX1 is required for definitive hematopoiesis and may regulate the emergence of hematopoietic stem cells from hematogenic endothelial cells (North et al., 1999; Yokomizo et al., 2001) . Differentiation of myeloid progenitor cells to granulocytes required RUNX1 (Tanaka et al., 1995; Ahn et al., 1998) , and RUNX1 is the most frequent target of chromosomal translocation associated with human leukemia (Look, 1997; Speck and Gilliland, 2002) . After discovering the involvement of AML1/RUNX1 in t(8;21) acute myelogenous leukemia, RUNX1/AML1 was identified as important in generating AML1-Evi1 in the t(3;21) acute myelogenous leukemia associated with therapy-related acute myelogenous leukemia, myelodysplastic syndrome and blast crisis of chronic myelogen- ous leukemia by Mitani et al. (1994) and Nucifora et al. (1993) . AML1/RUNX1 was also found to be involved in the most prevalent childhood acute lymphoblastic leukemia, t(12;21), which generates TEL/AML1 by Gary Gilliland's laboratory (Golub et al., 1995) .
In most cases, the chimeric genes involving the RUNX1 locus generated as a result of chromosomal translocations inhibit RUNX1 function, although they appear to enhance RUNX1 function in other cases. In general, the absence of or the reduced function of Figure 2 Comparison of amino-acid sequences of the RUNX proteins of various species. Species and database accession numbers for the respective Runx paralogs are: mRunx1, Mus musclus, Q03347; chRunx1, Gallus gallus, NP_990558; Xaml, Xenopus laevis, AAC41269; drRunx1, Danio rerio, NP_571678; mRunx2, Mus musclus, A48233; chRunx2, Gallus gallus, NP_989459; drRunx2a, Danio rerio, AAQ88389; drRunx2b, Danio rerio, AAR29000; hRunx3, Homo sapiens, AAH13362; drRunx3, Danio rerio, BAB17904; rayRunx3, Raja eglanteria, AAR11381; braRunx, Branchiostoma floridae, AAN08567; spRunt-1, Strongylocentrotus purpuratus, AAB03565; dmRunt, Drosophila melanogaster, P22814; ceRnt-1, Caenorhabditis elegans, NP_491679 Oncogenic potential of the RUNX gene family Y Ito RUNX1 blocks granulocytic differentiation, which is usually accompanied by cell proliferation. However, recent studies showed that the altered RUNX1 appears to regulate the cell cycle negatively. This controversy might be clarified through the analysis of stem cell activity. Attention has recently been focused on hematopoietic stem cells as a potential stage for critical initiation (Mulloy et al., 2002) If chimeric RUNX1 genes inactivate RUNX1 function to cause leukemia, then loss-of-function RUNX1 mutations may also cause myeloid leukemia. Indeed, sporadic and familial heterozygous and homozygous RUNX1 mutations occur in leukemia patients, predisposing them to the development of acute myeloid leukemia (Osato et al., 1999; Song et al., 1999) . Many more point mutations in RUNX1 have recently been identified and described in various types of leukemias, suggesting that the incidence of RUNX1 point mutations is comparable to that of classical chromosome translocations involving RUNX1 (see chapter by Osato.) In addition to loss-of-function mutations, gain-of-RUNX1 function mutations have recently been postulated and may have leukemogenic effects (Niini et al., 2000; Wotton et al., 2002) . For example, Down syndrome-related acute megakaryoblastic leukemia may be caused by an extra copy of RUNX1, since Down syndrome is caused by trisomy of chromosome 21 that harbors the RUNX1 locus. If this is true, overdose of RUNX1 would also be leukemogenic. As described above, haploinsufficiency of RUNX1 is known to be leukemogenic. It is important to examine why the level of RUNX1 expression must be so precisely regulated (also see chapter by Cameron and Neil.) Chromosomal translocations occur in about half of leukemia cases (Look, 1997) . Furthermore, at least three genetic changes are believed to be required to induce full-blown leukemia. Therefore, a large number of genes that contribute to leukemogenesis have yet to be identified. For this purpose, the murine retroviral mutagenesis strategy is being explored, and some 300 candidate genes have been identified thus far (Akagi et al., 2004) . Many of these genes are already known to be involved in other types of human cancers. Therefore, this strategy appears to be an efficient, high-throughput method of identifying candidate cancer genes DePinho and Jacks, 1999) . Classification of potential cancer-causing human genes identified by this approach may elucidate cellular pathways required to induce malignant conversion of normal cells.
RUNX1 functions in hematopoiesis have also been studied using Drosophila and zebra fish. Utpal Banerjee's laboratory has been studying the role of lozenge, the second Runt-related gene in Drosophila initially studied in eye development (Daga et al., 1996) . A RUNX1 homolog was found in the zebra fish hematopoiesis model (Kataoka et al., 2000; Burns et al., 2002; Crosier et al., 2002) ..
RUNX2
Mouse Runx2, first identified as PEBP2aA in 3T3 cells transformed by H-ras, was used to initially demonstrate that the RUNX family is the DNA-binding subunit of heterodimeric transcription factors, but the physiologi- Figure 4 A diagram of RUNX1 protein with functional domains, sites of phosphorylation (Tanaka et al., 1996; Wee et al., 2002) and acetylation (Yamaguchi et al., 2004) and the location of the interacting proteins (see below). RD: Runt domain (Kagoshima et al., 1993) ; AD: transcription activation domain, TE1, TE2 and TE3: subelements within AD (Ito, 1999); ID: transcription inhibition domain (Kanno et al., 1998) ; NLS: nuclear localization signal, NRDBn and NRDBc: negative regulatory region for DNA binding in N-terminal (n) and C-terminal (c) . NRHn and NRHc: negative regulatory region for heterodimerization in Nterminal (n) and C-terminal (c) . NMTS: nuclear matrix targeting signal (Zeng et al., 1997) . References for interacting proteins: ALY (Bruhn et al., 1997) (Li FQ et al., 2004) , PAX5 (Libermann et al., 1999) , mSin3A (Lutterbach et al., 2000) , MEF (Mao et al., 1999) and CEBP/a, PU.1 (Petrovick et al., 1998) cal role was unclear (Ogawa et al., 1993b) . The laboratories of Komori et al. (1997) and Otto et al. (1997) made Runx2-deficient mice and showed that Runx2 is essential for the maturation of osteoblasts and, together with the study by Ducy et al. (1997) , revealed that Runx2 plays a key role in osteogenesis. This observation was immediately linked to the discovery by Mundlos et al. (1997) , Otto et al. (1997) and Lee et al. (1997) that the human autosomal dominant bone disease cleidocranial dysplasia is caused by haploinsufficiency of RUNX2. Although RUNX2
has not yet been implicated in human cancers, Runx2 oncogenic activity has been demonstrated in mice. Runx2 cooperates strongly to induce T-cell lymphoma in transgenic mice ectopically expressing c-myc in T-lymphocytes (Stewart et al., 1997) . In addition, several laboratories have also identified Runx1 and Runx3 as cooperating genes by the retroviral mutagenesis method. Interestingly, Runx genes act as oncogenes rather than tumor suppressor genes in this system. The dual roles of RUNX family genes in oncogenesis are fully discussed in the chapter by Cameron and Neil in this issue.
Another interesting feature revealed by this system is that the retrovirus consistently activates the distal promoter, rather than the frequently transcribed proximal promoter (Stewart et al., 1997) . The proteins transcribed from these two transcripts have different amino-terminal sequences, the significance of which has not yet been determined (Cameron et al., 2003) . The roles of these two promoters in development and oncogenesis must be further clarified.
RUNX3 and gastric cancer
Identification of tissues expressing Runx3 is complicated, partly because different methods of detection generate different results. Temporal and spatial changes in expression also add to the complexity. Nevertheless, Runx3 appears to be expressed ubiquitously in many cell types including epithelial cells, mesenchymal cells and blood cells, although the expression in peripheral nervous system including dorsal root ganglion neurons, epithelial cells in the adult gastrointestinal tract and hematopoietic cells seems to be especially prominent. Therefore, Runx3-deficient mice are expected to show a wide variety of phenotypes.
Runx3 knockout mice were generated in the laboratory of Levanon et al. (2002) and in my own laboratory in close collaboration with Suk-Chul Bae and Kosei Ito . Phenotypes of several different tissues in these knockout mice have been described. Among these, the phenotype that is most closely associated with the oncogenic activity of RUNX3 is that of stomach epithelium. Hiroshi Fukamachi has had extensive experience studying gastric epithelial cell development and has established a primary culture and cell lines of gastric epithelial cells. Fukamachi's work, in combination with careful phenotype analyses by Kosei Ito, has enabled the identification of the gastric phenotype. SukChul Bae and my laboratory collaborated with Chohei Sakakura (a surgical gastroenterologist) to analyse gastric cancer cell lines and surgically dissect cancer tissues. The analyses revealed that the loss of expression of RUNX3 is causally related to gastric cancer. In Runx3À/À mice, the gastric mucosa undergoes hyperplasia due to increased resistance of gastric epithelial cells to TGF-b growth inhibitory activity and TGF-bmediated apoptosis. Inactivation of RUNX3 in gastric cancer occurs by the combination of a hemizygous deletion and gene silencing due to hypermethylation of the promoter region, and appears to occur during the early as well as the progressive stages of the disease. One of the most critical observations strongly implicating RUNX3 as a gastric cancer tumor suppressor was the discovery in a patient sample of a RUNX3 point mutation that resulted in the substitution of arginine with cystine in the conserved region and complete inactivation of the tumor suppressive activity in the nude mice tumor formation assay. The critical mutation was found by Atsushi Kaneda, Toshizawa-Ushijima and Takashi Sugimura .
Interestingly, intestinalization of gastric epithelium is closely associated with gastric carcinogenesis. In this respect, it is worth noting that RUNX3 is downregulated in intestinal metaplasia . A critical question is whether RUNX3 inactivation induces intestinal metaplasia. Cdx2 is one of the mammalian homologs of a Drosophila caudal gene that controls the anterior-posterior patterning. Cdx2 is expressed exclusively in intestinal mucosa, but not in stomach mucosa (Yuasa, 2003) . However, expression occurs in gastric mucosa after intestinal metaplasia. Furthermore, ectopic expression of Cdx2 in gastric epithelium induces intestinal metaplasia (Mutoh et al., 2002; Silberg et al., 2002) . Therefore, Runx3 might inhibit Cdx2 expression in normal gastric mucosa. The precise relationship between Runx3 and Cdx2 in gastric gland development and induction of gastric cancer must be determined.
RUNX3 is involved in diverse biological pathways. Roles of Runx3 in T-cell development (Taniuchi et al., 2002; Woolf et al., 2003) and in dendritic cells (Fainaru et al., 2004) have been described. In the absence of Runx3, proprioceptive neuronal axons cannot reach the physiological motorneuronal targets in the spinal cord (Inoue et al., 2002; Levanon et al., 2002) .
RUNX and TGF-b signaling
The TGF-b superfamily transmits signals through transmembrane receptors, which activate signal transduction molecules known as Smads. Bone morphogenetic protein (BMP) receptors and TGF-b receptors activate different sets of Smad proteins. These receptorregulated Smad proteins interact with a common Smad and are translocated into the nucleus where they bind to transcription factors to regulate target gene expression. Smad proteins activated by the receptors for both BMP and TGF-b directly interact with RUNX proteins (Hanai et al., 1999) . Although multiple transcription factors interact with receptor-regulated TGF-b-specific Smad proteins, only a limited number of transcription factors interact with BMP-specific Smad proteins. Since RUNX1, RUNX2 and RUNX3 all interact with both TGF-b-and BMP-specific Smad proteins, RUNX transcription factors appear to be uniquely associated with the TGF-b superfamily signaling pathway (see chapter by Miyazono et al.) . The TGF-b signal also transcriptionally activates the Runx2 gene (Lee et al., 2000) , although the inhibition of Runx2 expression by TGF-b was also reported (Alliston et al., 2001) .
The relationship between RUNX3 and the TGF-b signaling pathway is of particular interest. The RUNX3 gene is located on 1p36 (Levanon et al., 1994; Bae et al., 1995) , where LOH is often reported in many types of cancers including stomach, colon and pancreatic cancer (Weith et al., 1996) . Therefore, a major tumor suppressor has been predicted to reside on 1p36. On the other hand, the TGF-b-mediated signal transduction pathway is regarded as a tumor suppressor pathway, since receptors and Smad proteins are often altered in many different types of cancers (reviewed by Massague et al., 2000; Derynck et al., 2001) . Therefore, RUNX3 may be the long sought-after tumor suppressor on 1p36 and the RUNX3 protein may be a target of the TGF-b-mediated tumor suppressor pathway (reviewed by Ito and Miyazono, 2003) . If this model is correct, RUNX3 could be involved in many cancers in addition to gastric cancer. A possible involvement of RUNX3 has already been reported for cancers of the pancreas, bile duct (Wada et al., 2004) and lung (Li Q et al., 2004) . Studies to further examine this possibility are underway in various laboratories.
The TGF-b superfamily is involved in the regulation of numerous biological reactions, including cell growth or inhibition, differentiation, apoptosis and angiogenesis. Since RUNX proteins appear to be one of the major targets of Smad signaling, they may also be involved in the regulation of a variety of biological phenomena. Research conducted in various laboratories suggests that this prediction may indeed be true. RUNX proteins, therefore, may contribute to cancer induction by a variety of methods, including the dysregulation of cell cycle control, apoptosis, differentiation and angiogenesis.
New frontiers and problems in RUNX research
Re-evaluation of subcellular localization of RUNX proteins: interaction with STAT protein
The level of expression of RUNX proteins is generally low. Therefore, subcellular localization of RUNX proteins has been studied largely via exogenously expressed RUNX proteins in fibroblasts and leukemic cells. In such cases, immunocytochemistry shows that RUNX proteins are localized in the nucleus, whereas exogenously expressed PEBP2b/CBFb is in the cytoplasm. In agreement with these findings, RUNX proteins have nuclear localization signals, while PEBP2b/CBFb has putative nuclear export signals. Since these two subunits do not associate even when they are expressed in the same cells, the process of heterodimerization is assumed to be controlled by some unknown mechanism. It is not even clear where these two subunits interact to dimerize (Lu et al., 1995) . Phosphorylation of S104 of Runx2 is suggested to abolish heterodimerization, but details of the mechanism are still unknown (Wee et al., 2002) .
Recently, Takayanagi's laboratory showed that Stat1-deficient mice show accelerated osteoblast activities for bone formation (Kim et al., 2003) . They found that a latent form of Stat1 protein present in osteoblast cytoplasm binds to Runx2, retaining it in the cytoplasm and preventing it from functioning as a transcription factor, while Runx2 enhances osteoblast activities in the absence of Stat1. They propose that Stat1 functions as a cytoplasmic attenuator of Runx2 in osteoblast differentiation. This Stat1 activity appears to be independent of its phosphorylation-dependent activation or transcriptional stimulation. BMP stimulates bone formation. Smad proteins specifically activated by BMP interacts with RUNX proteins and stimulate osteogenesis (Lee et al., 2000; Zhang et al., 2000) . Interestingly, the interaction between Stat1 and Runx2 appears to be weakened upon stimulation of the cells with BMP. The authors speculate that upon stimulation by BMP, Runx2 swaps interacting partners (from Stat1 to Smad1) and translocates into the nucleus to regulate the transcription of target genes. This is a provocative idea warranting rigorous examination. Kim et al. (2003) did not examine whether PEBP2b/ CBFb plays any role in Stat1/Runx2 interaction. RUNX proteins alone are unstable, since they are subject to ubiquitination followed by proteolytic degradation by proteasome enzymes (Huang et al., 2001) . PEBP2b/CBFb prevents ubiquitination of RUNX proteins by heterodimerizing with RUNX proteins. Is the cytoplasmic Runx2 bound to Stat1 associated with PEBP2b/CBFb? Alternatively, Stat1 may prevent ubiquitination of the Runt domain, since Stat1 appears to interact with Runx2 through the Runt domain. This RUNX protein regulation by cytoplasmic retention by the Stat protein is not yet known to be widely operational in many cell types. However, it is necessary to examine whether the mechanism is commonly used by all RUNX members at least in some cell types.
Upstream signals
The TGF-b superfamily undoubtedly comprises major upstream signals to control the function of PEBP2/CBF (see above). As mentioned above, a signal controlling Stat1 protein, probably BMP, regulates RUNX2 function. In addition, phosphorylation of RUNX1 at S249 and Ser266 by ERK kinase enhances transcriptional activation, although the signal that induces this phosphorylation has not been studied yet (Tanaka et al., 1996) . RUNX2 appears to be negatively regulated by the phosphorylation of two conserved serines, S104 and S451. Phosphorylation of S104 appears to disrupt the heterodimerization of RUNX2 with PEBP2b/CBFb, which enhances the metabolic stability of RUNX2. On the other hand, S451 resides within the C-terminal transcription inhibition domain of RUNX2 and the phosphorylation of this residue appears to be involved in the negative regulation of RUNX2 function (Wee et al., 2002) . Unfortunately, the signals controlling these phosphorylations are not known.
Three RUNX proteins have the PPPY sequence within their transcription activation domain. The proline-rich motif PPxY is present in a broad range of proteins and is known to interact with WW domaincontaining proteins (Sudol and Hunter, 2000) . One of the WW domain containing proteins, Yes associate protein (YAP), interacts with RUNX2 through this motif (Yagi et al., 1999) . The yes gene is a tyrosine kinase containing proto-oncogene closely related to csrc. Both are associated with the cell surface membrane. YAP can be present on the cell surface associated with Yes, in the cytoplasm associated with 14-3-3, and in the nucleus associated with RUNX2. YAP may transduce signals from the cell surface to the nucleus. Gary Stein and his associates addressed this issue (Zaidi et al., 2003) . This group has been studying subnuclear structures for a long time and identified a nuclear matrix targeting signal (NMTS) close to C-terminal end of RUNX2 (Zeng et al., 1997) . Earlier reports indicated that c-src-deficient mice show accelerated osteoblast differentiation. YAP is targeted to a subnuclear site by RUNX2 in a PY motif-dependent manner and inhibits the osteogenic RUNX2 function. Activated Yes phosphorylates YAP on tyrosine residues, which is required for the targeting of YAP to RUNX2 in the subnuclear site. Furthermore, recruitment of YAP to a subnuclear site to associate with RUNX2 appears to be required for the regulation of the ostocalcin promoter. These results suggest that Src/Yes signals are transduced by YAP to the nucleus where the Runx2/YAP complex regulates skeletal gene expression. Since the PY motif is present in all three RUNX proteins, the biological roles of this motif in each RUNX protein must be examined to determine if this motif acts as a receptor of signals from the cell surface to the nucleus to regulate RUNX protein function (see chapter by Stein et al.).
The above observations suggest that RUNX proteins are regulated by multiple upstream signals. Elucidating how these signals are coordinated and integrated in each biological system will be challenging.
Downstream targets
The RUNX family genes regulate both growth and differentiation of cells. Identification of the target genes involved in both pathways is important for understanding the oncogenic processes mediated by this family of genes. Multiple genes are known to be downstream targets of RUNX1 and RUNX2, and a smaller number of RUNX3 target genes are described so far. Cell cycle regulator genes, like p21waf-1, are likely to be important targets involved in carcinogenic processes (Linggi et al., 2002) . Scott Hiebert described p19ARF as an important target for RUNX proteins in oncogenesis (Linggi et al., 2002) . TGF-b-induced apoptosis observed in gastric epithelium is greatly reduced in Runx3-null mice . Therefore, some proapoptotic genes may be important carcinogenic targets of RUNX3. Since the dysregulation of differentiation seems to be critical in carcinogenesis, RUNX family regulatory mechanisms of differentiation should be studied rigorously to better understand carcinogenic processes.
Chromatin and epigenetic regulation
Runx3 may have a unique role in T-cell development (Taniuchi et al., 2002; Woolf et al., 2003) . Immature thymocytes lacking CD4 and CD8 coreceptors differentiate into double-positive (CD4 þ CD8 þ ) cells that are selected to become either CD4 þ CD8À helper cells or CD4ÀCD8 þ cytotoxic cells. A transcriptional silencer regulates the expression of CD4 in both immature and CD4ÀCD8 þ thymocytes. Runx1 is required for active repression in double-negative thymocytes, whereas Runx3 is necessary for epigenetic silencing in cytotoxic lineage thymocytes. Since Runx3 is required specifically for lineage-specific CD4 silencing, Runx3 may be a key molecule involved in regulating lineage specificity. In the absence of Runx3, CD4ÀCD8 þ cells are not formed and CD4 þ CD8 þ cells with cytotoxic cell markers accumulate (see chapter by Taniuchi and Littman) .
Runx3 may also be involved in determining lineage specificity in other tissues. Runx3 is maximally expressed in well-differentiated chief cells and in surface epithelial cells in gastric mucosa . Runx3 may be required for lineage-specific differentiation of chief cells and surface epithelial cells. Dysregulated differentiation of these cells in the absence of Runx3 may result in the formation of cells with abnormal cell type specific markers. Since RUNX3 is a strong candidate for a gastric cancer tumor suppressor, cancer cells may develop from such abnormally differentiated cells.
In T-cell development, Runx1 may guide the BAF chromatin-remodeling complex to both the CD8 and CD4 loci to initiate chromatin opening for subsequent recruitment of coactivators or corepressors (Taniuchi et al., 2002) . Thus, hematopoietic stem cells or myeloid progenitor cells may lose their capacity for differentiation and lineage specificity when Runx1 is absent. Of note, myeloid leukemia cells sometimes additionally express lymphoid markers (Kita et al., 1992; Adriaansen et al., 1993) .
Autoimmune diseases
Three recently reported articles (Prokunina et al., 2002; Tokuhiro et al., 2003; Helms et al., 2003) revealed a strong link between RUNX1 and the autoimmune diseases known as systemic lupus erythematosus Oncogenic potential of the RUNX gene family Y Ito (SLE), rheumatoid arthritis and psoriasis. The programmed cell death 1 gene (PDCD1 or PD-1) was considered to be the strongest candidate for SLE. Single-nucleotide polymorphisms (SNPs) found in a RUNX1-binding site within an intron of PDCD1 that disrupts RUNX1 binding is tightly linked to SLE (Prokunina et al., 2002) . By investigating the genetic contribution of the cytokine gene cluster in chromosome 5q31 to rheumatoid arthritis, Tokuhiro et al. (2003) found a significant association between the organic cation transporter gene SLC22A4 and the disease. An intronic SNP in a RUNX1-binding site of SLC22A4 reduces the binding of RUNX1 and affects the expression of SLC22A4. SNP was also located in the RUNX1 gene that is also strongly associated with rheumatoid arthritis (Tokuhiro et al., 2003) . Psoriasis is a chronic inflammatory skin disorder. The linkage analysis shows that one of the strongly associated genes has two peaks on chromosome 17p25. The first peak is associated with an SNP between the two genes transcribed in tail-to-tail orientation, SLC9A3R1 (also called EBP50 and NHERF1) and NAT9. SLC9A3R1 is a PDZ domaincontaining phosphoprotein that associates with members of the ezrin-radixin-moesin family. NAT9 is a new member of the N-acetyltransferase family. In this case, too, SNP disrupts the binding site for RUNX1 (Helms et al., 2003) . These observations reinforce the important roles of RUNX1 in the immune system and open an exciting new research field.
Widespread involvement of RUNX3 in diverse cancers
RUNX3 is strongly suspected to be a gastric cancer tumor suppressor, and may also be involved in other, perhaps many other, types of cancer. Evidence suggesting the involvement of RUNX3 in cancers of the pancreas, bile duct and lung has been published (Li Q et al., 2004; Wada et al., 2004) . RUNX3 may also be involved in hepatocellular carcinoma, colorectal cancer and neuroblastoma (to be published). Why would RUNX3 be involved in so many different cancer types? Owing to its broad involvement as a guardian of the genome and in critical regulatory cell growth pathways (cell cycle regulation and apoptosis), the p53 gene is inactivated in 50% of various types of human cancers. RUNX3 may also be involved in some critical aspects of carcinogenesis. Recent observations that RUNX2 is involved in metastasis of breast cancer cells suggest even wider involvement of RUNX genes in carcinogenic processes (Barnes et al., 2003) . Identification of the fundamental biological processes under the control of RUNX3 will be one of the major challenges in RUNX research in the years ahead.
